Table 3: Therapeutic approach according to the presence of cardiovascular disease.
Overall | CV disease | No CV disease | P | |
Antithrombotic drugs | ||||
Antiplatelets (%) | 14.2 | 44.6 | 8.2 | 0.0001 |
Anticoagulants (%) VKA DOACs |
4.6 4.1 0.5 |
15.1 13.6 1.5 |
2.6 2.3 0.3 |
0.0001 0.0001 0.0001 |
Nonsteroidal anti-inflammatory drugs (%) | 12.7 | 11.7 | 12.9 | NS |
Antihypertensive drugs | ||||
Number of antihypertensive drugs | 1.7 ± 0.9 | 2.0 ± 1.0 | 1.6 ± 0.9 | 0.0001 |
Number of antihypertensive drugs 0 1 2 3 > 3 |
6.3 40.2 34.7 15.7 3.1 |
4.4 28.5 36.5 24.3 6.3 |
6.7 42.5 34.3 14.0 2.5 |
0.0001 |
ARB (%) | 44.9 | 48.8 | 44.2 | NS |
Diuretics (%) | 44.6 | 48.2 | 43.9 | NS |
ACEi (%) | 36.6 | 32.3 | 37.5 | 0.044 |
Calcium channel blockers (%) | 22.5 | 31.4 | 20.7 | 0.0001 |
Beta Blockers (%) | 18.3 | 33.8 | 13.1 | 0.0001 |
Alpha blockers (%) | 3.5 | 4.4 | 3.2 | NS |
Lipid lowering drugs | ||||
Number of lipid lowering drugs | 0.7 ± 0.5 | 1.0 ± 0.5 | 0.7 ± 0.5 | 0.0001 |
Number of lipid lowering drugs 0 1 2 3 |
27.8 66.9 5.2 0.1 |
15.0 75.5 9.1 0.4 |
30.3 65.3 4.4 0 |
0.0001 |
Statins (%) | 67.4 | 79.7 | 65.0 | 0.0001 |
Fibrates (%) | 6.0 | 6.8 | 5.9 | NS |
Ezetimibe (%) | 1.4 | 7.8 | 2.2 | 0.0001 |
Others (%) | 0.8 | 0.6 | 0.8 | NS |
Antidiabetic drugs | ||||
Number of antidiabetic drugs | 1.6 ± 0.9 | 1.5 ± 0.9 | 1.6 ± 0.9 | NS |
Number of antidiabetic drugs 0 1 2 3 4 |
10.3 41.1 33.8 12.2 2.6 |
8.4 45.8 32.2 11.2 2.4 |
10.7 40.2 34.1 12.4 2.6 |
NS |
Metformin | 75.0 | 67.3 | 76.5 | 0.011 |
Dipeptidyl peptidase 4 inhibitors | 30.4 | 31.8 | 30.2 | NS |
Insulin | 20.7 | 29.0 | 19.1 | 0.004 |
Sulfonylureas | 14.5 | 11.2 | 15.2 | NS |
Glinides | 4.6 | 4.7 | 4.6 | NS |
Sodium-glucose Cotransporter-2 inhibitors | 4.2 | 3.3 | 4.4 | NS |
GLP-1 receptor agonists | 3.0 | 3.7 | 2.9 | NS |
Thiazolidinediones | 2.6 | 2.3 | 2.6 | NS |
CV: Cardiovascular; VKA: Vitamin K Antagonists; DOACs: Direct Oral Anticoagulants; ARB: Angiotensin Receptor Blockers; ACEi: Angiotensin Converting Enzyme inhibitors.